المؤلفون: Yair Lotan, Vitaly Margulis, Aditya Bagrodia, Solomon L. Woldu, Laura Maria Krabbe, Ahmet M. Aydin, Martin Boegemann, Ryan Hutchinson

المصدر: OncoTargets and therapy

مصطلحات موضوعية: atezolizumab, 0301 basic medicine, Oncology, medicine.medical_specialty, Metastatic Urothelial Carcinoma, medicine.medical_treatment, Context (language use), Review, Malignancy, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, PDL1, Internal medicine, medicine, Pharmacology (medical), Chemotherapy, Bladder cancer, business.industry, Immunotherapy, medicine.disease, metastatic, 030104 developmental biology, MPDL3280A, Tolerability, 030220 oncology & carcinogenesis, bladder cancer, immunotherapy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c24b0b19c02c3fddf74b04427923c6Test
https://doi.org/10.2147/ott.s109453Test

المؤلفون: Katarzyna Guzik, Przemyslaw Grudnik, Bartosz J. Zieba, Krzysztof M. Zak, Grzegorz Dubin, Bogdan Musielak, Alexander Dömling, Tad A. Holak

المساهمون: Drug Design, Medicinal Chemistry and Bioanalysis (MCB)

المصدر: Oncotarget
Oncotarget, 7(21), 30323-30335. Impact Journals LLC

مصطلحات موضوعية: Models, Molecular, 0301 basic medicine, Magnetic Resonance Spectroscopy, CLINICAL ACTIVITY, Programmed Cell Death 1 Receptor, drug protein binding, Plasma protein binding, ANTI-PD-L1 ANTIBODY, Pharmacology, Crystallography, X-Ray, drug research, THERAPY, B7-H1 Antigen, PROTEIN-PROTEIN INTERACTIONS, 0302 clinical medicine, Checkpoint inhibitor, binding affinity, conformational transition, Molecular Structure, Drug discovery, Chemistry, CHECKPOINT BLOCKADE, article, Ligand (biochemistry), Small molecule, unclassified drug, bms 8, Oncology, protein stability, MPDL3280A, 030220 oncology & carcinogenesis, protein protein interaction, CANCER-IMMUNOTHERAPY, immunotherapy, Immunotherapy, drug potency, Protein Binding, Signal Transduction, Research Paper, crystal structure, bms 37, medicine.drug_class, small molecule, Monoclonal antibody, Protein–protein interaction, Small Molecule Libraries, 03 medical and health sciences, Protein Domains, complex formation, inhibition kinetics, medicine, Humans, controlled study, human, nuclear magnetic resonance spectroscopy, STABILITY, drug targeting, bms 202, programmed death 1 receptor, molecular dynamics, NMR, programmed death 1 ligand 1, drug structure, checkpoint inhibitor, 030104 developmental biology, Targeted drug delivery, protein inhibitor, Biophysics, bms 242, drug synthesis, X-ray structure, INHIBITORS

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4077c489c1a3e54f918f43d3ca7d076cTest
https://hdl.handle.net/11370/66b38ebe-19cb-4ca3-bd38-d873a99853beTest

المؤلفون: Jedd D. Wolchok, David B. Page, Jarushka Naidoo

المصدر: British Journal of Cancer

مصطلحات موضوعية: Cancer Research, anti-PD-L1, medicine.medical_treatment, Ipilimumab, Immune system, tremelimumab, Antigen, Neoplasms, medicine, Humans, Antibody-dependent cell-mediated cytotoxicity, nivolumab, anti-CTLA4, business.industry, Immunotherapy, BMS-936559, Immune checkpoint, Oncology, MPDL3280A, Immunology, anti-PD-1, Minireview, Nivolumab, business, Tremelimumab, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23d6166bdfa37af6284efa3ef85ad2b5Test
http://europepmc.org/articles/PMC4264429Test

المؤلفون: Juergen Wolf, Rieke Fischer, Michael Brockmann, Thomas Zander, Julie George, Sascha Ansén, Wim Timens, Michael von Bergwelt-Baildon, Anne M. Schultheis, Erich Stoelben, Matthias Scheffler, Reinhard Buettner, Harry J.M. Groen, Andreas H. Scheel, Sven Perner, Sebastian Michels, Martin Hellmich

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Groningen Research Institute for Asthma and COPD (GRIAC)

المصدر: OncoImmunology, 5(5):1131379. Taylor & Francis Group

مصطلحات موضوعية: 0301 basic medicine, Oncology, PD-L1, medicine.medical_specialty, early stage NSCLC, DEATH-LIGAND 1, medicine.medical_treatment, Immunology, IMMUNE, MELANOMA, Pembrolizumab, Biology, medicine.disease_cause, ANTIBODY MPDL3280A, 03 medical and health sciences, 5H1, 0302 clinical medicine, TUMOR, Internal medicine, Checkpoint inhibition, medicine, Immunology and Allergy, BREAST-CANCER, Lung cancer, PEMBROLIZUMAB, non-small cell lung cancer, Original Research, genetic alterations, Melanoma, NIVOLUMAB, ADENOCARCINOMA, Immunotherapy, medicine.disease, B7-H1, 030104 developmental biology, 030220 oncology & carcinogenesis, immunohistochemistry, Cancer research, biology.protein, Adenocarcinoma, KRAS, Antibody

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4fe71ef809691242aa09ab32f1d86cfTest
https://research.rug.nl/en/publications/45183bcf-9331-4a75-bb12-06f86907305bTest